LLY Eli Lilly and Company
Company Analysis
Latest News
🟢 Eli Lilly is trading 3.27% up today after groundbreaking at a $5 billion Virginia facility
Eli Lilly is trading 3.27% up at $1,312.29 after coverage linked the rise to its October 22, 2026, groundbreaking on a $5 billion manufacturing facility in...
Eli Lilly and Mubadala Bio Announce Strategic Collaboration for GLP-1 Medicines in Abu Dhabi
Eli Lilly and Company collaborates with Mubadala Bio. This partnership advances localized packaging and logistics for Lilly's GLP-1 medicines in Abu Dhabi. The...
🟢 Eli Lilly is trading 4.35% up on October 20, 2026, amid healthcare gains; catalyst unconfirmed
Eli Lilly is trading 4.35% higher at $1,294.30, supported by healthcare strength; no single catalyst is confirmed. - Healthcare rose 2.12% during the regular...
Eli Lilly Strikes Up-to-$1.1 Billion Drug Delivery Deal With Metis TechBio
Eli Lilly and Company has entered a strategic collaboration with Hong Kong-listed Metis TechBio to develop tissue-specific drug delivery technologies. The...
🟢 Eli Lilly is trading 3.98% up today as investors rotate into defensive healthcare stocks
Eli Lilly is trading 3.98% up at $1,256.84 as defensive healthcare-sector demand supports the move. - Investors rotated into defensive healthcare stocks after...
🟢 Eli Lilly is trading 3.45% up on October 14, 2026, amid a healthcare sector rally
Eli Lilly is trading at $1,206.78, up 3.45%, alongside a healthcare sector gain of 1.64% in the regular session; no direct link has been established. -...
Eli Lilly's Oral Obesity Drug Foundayo Sees Weekly Prescriptions Dip
IQVIA data shows a downturn in weekly U.S. prescriptions for new oral obesity drugs from Eli Lilly and Novo Nordisk. Prescriptions for Lilly's Foundayo fell...
🔴 Eli Lilly is trading 3.39% down on October 8, 2026, amid oil-supply and rate concerns
Eli Lilly is trading at $1,148.38, down 3.39%, amid broad risk-off pressure; no clear company-specific catalyst has been identified. - Attacks in Saudi Arabia...
🟢 Eli Lilly is trading 3.02% up today as healthcare gains on defensive demand
Eli Lilly is trading 3.02% up at $1,192.45, outperforming a weaker broader market as healthcare stocks draw defensive buying. - Healthcare is up 1.25%, with...
Eli Lilly and insitro Make AI Drug Discovery Models Available to Biotech Companies
Eli Lilly and Company partnered with AI firm insitro. They announced advanced machine learning models are now accessible to select biotech companies. These...
Eli Lilly Expands Drug Discovery Pact with Gate Bioscience for Over $870 Million
Eli Lilly expanded its research and licensing agreement with Gate Bioscience. The expansion adds over $870 million in potential value to their existing...
Eli Lilly Wins First-Line FDA Approval for Jaypirca in CLL/SLL
The U.S. Food and Drug Administration (FDA) expanded approval of Eli Lilly’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with chronic...
Lilly Says Foundayo May Cut Modeled 10-Year Diabetes Risk by 57%
Eli Lilly said post-hoc analyses of its ATTAIN-1 trial found that its oral GLP-1 drug Foundayo (orforglipron) was associated with lower predicted long-term...
Eli Lilly Reports 20.8% Weight Loss With Retatrutide in Phase 3 Trial
Eli Lilly reported detailed results from its TRIUMPH-2 Phase 3 trial of investigational retatrutide in adults with type 2 diabetes and obesity. The results...
Eli Lilly's EloraTZP Delivers 23.3% Weight Loss in Phase 2b Trial
Eli Lilly reported positive results from a Phase 2b trial of EloraTZP, an investigational combination of eloralintide and tirzepatide. The trial enrolled 367...
Lilly Finds Zepbound Linked to More Weight Loss Than High-Dose Wegovy
Eli Lilly (LLY) reported results from an indirect treatment comparison suggesting its weight-loss drug Zepbound was associated with greater weight loss than...
Eli Lilly Says Foundayo Outperformed Novo's Oral Semaglutide in Indirect Comparison
Eli Lilly announced new data suggesting its oral GLP-1 drug Foundayo (orforglipron) provided greater weight loss and blood sugar control than Novo Nordisk's...
Eli Lilly Seeks Bigger Deals, Fueled by GLP-1 Cash Flow
Eli Lilly CEO David Ricks said the company is pursuing larger acquisitions to support future growth. In an interview with Bloomberg, he said future deals could...
🟢 Eli Lilly is trading 3.06% up today after FDA approval of once-weekly Onswik insulin
Eli Lilly is trading 3.06% up at $1,186.24 after FDA approval of Onswik, its once-weekly basal insulin for adults with type 2 diabetes. - Onswik offers an...
Home Depot Co-Founder Ken Langone Predicts Eli Lilly's Stock Could Reach $2,000
Ken Langone, Home Depot co-founder, expressed a highly optimistic outlook for Eli Lilly. He suggested the stock could reach $2,000 per share within three to...